Emergent BioSolutions Gets $22.3 Million BioThrax Order Modification From Department of War

Emergent BioSolutions received a modification exercising an option period under its existing delivery order, valued at up to $22.3 million, to supply BioThrax (Anthrax Vaccine Adsorbed) to the U.S. Department of War. The company announced the order on November 4, 2026, according to Business Wire. The first delivery, valued at approximately $7.4 million, begins this year, and remaining deliveries are expected in 2027.

Inside the BioThrax Delivery Order

The order sits under Emergent's existing indefinite-delivery/indefinite-quantity contract, W911SR24D0001, led by the Portfolio Management Executive for Chemical, Biological, Radiological and Nuclear Defense in collaboration with the Defense Health Agency. BioThrax is supplied for use by all branches of the U.S. military as pre-exposure prophylaxis for anthrax disease. Emergent BioSolutions is a Gaithersburg, Maryland-based biodefense and specialty life sciences company that develops and delivers medical countermeasures for biological threats and opioid overdose emergencies.

"We're pleased to continue supporting the Department of War's efforts to maintain preparedness against critical biological threats like anthrax," said Paul Williams, senior vice president, head of products business, global government and public affairs at Emergent. "Delivering dependable access to BioThrax helps protect our nation's service members who have an elevated risk of anthrax exposure."

The award builds on Emergent's anthrax work with the U.S. government. In August 2026, the company received a contract modification valued at approximately $24 million to supply CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) to the Biomedical Advanced Research and Development Authority for anthrax preparedness efforts.

Emergent's Recent Contract and Financing Record

According to akta.pro company records, Emergent closed a $150 million term loan with OrbiMed in April 2026 and amended its Wells Fargo asset-based revolver to up to $50 million, extending maturities to April 2031. The same records show first-quarter 2026 revenue of $156 million, a 30% decline from $222.2 million in the first quarter of 2025, driven by declines in anthrax and smallpox medical countermeasures.

Earlier Emergent BioSolutions Developments

On November 2, 2026, Emergent reported third-quarter 2026 revenue of $110 million, down 52% year-over-year, and a net loss of $32.7 million, according to Stock Titan. The loss was driven by debt repurchases and a $24 million contract modification, with an adjusted net loss of $18.7 million.

On October 16, 2026, Emergent announced that CFO Richard S. Lindahl will retire effective December 31, 2026, and that Frank Vargo will serve as interim CFO starting January 1, 2027, Stock Titan reported. Lindahl will serve as senior executive advisor through March 31, 2027, supporting the transition.

BioThrax Deliveries Into 2027

The first BioThrax delivery under the modification begins this year, and the remaining deliveries are expected in 2027.